Across TCGA pan-cancer cohorts, UBE2J1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated UBE2J1 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher UBE2J1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBE2J1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LGG, and LUSC are the cancer types where UBE2J1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.139	0.685	.003	24	view →
LGG	DFS	Median	All	0.080	0.833	<.001	12	view →
LUSC	OS	Median	III,IV	0.011	0.684	<.001	12	view →
UCEC	DFS	Median	All	0.955	0.620	.024	8	view →
SARC	DFS	Median	All	0.006	0.611	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: UBE2J1 tumor-vs-normal RNA expression · all UBE2J1 data types